CN110678186A - 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 - Google Patents

包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 Download PDF

Info

Publication number
CN110678186A
CN110678186A CN201880030083.5A CN201880030083A CN110678186A CN 110678186 A CN110678186 A CN 110678186A CN 201880030083 A CN201880030083 A CN 201880030083A CN 110678186 A CN110678186 A CN 110678186A
Authority
CN
China
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
injection
crystalline form
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030083.5A
Other languages
English (en)
Chinese (zh)
Inventor
克里斯多佛·J·伯恩斯
丹尼尔·C·佩维尔
路易吉·谢里
蒂莫西·亨克尔
丹尼尔·麦加里
劳伦斯·罗森
格拉尔德·布伦纳
吉恩·巴普蒂斯特·阿林
安娜·费尔南德斯卡萨雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunding Xinyao Singapore Ltd
Original Assignee
VenatoRx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VenatoRx Pharmaceuticals Inc filed Critical VenatoRx Pharmaceuticals Inc
Priority to CN202311312855.3A priority Critical patent/CN117398398A/zh
Publication of CN110678186A publication Critical patent/CN110678186A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880030083.5A 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途 Pending CN110678186A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311312855.3A CN117398398A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762467752P 2017-03-06 2017-03-06
US201762467750P 2017-03-06 2017-03-06
US62/467,752 2017-03-06
US62/467,750 2017-03-06
US201762564990P 2017-09-28 2017-09-28
US201762564989P 2017-09-28 2017-09-28
US62/564,990 2017-09-28
US62/564,989 2017-09-28
PCT/US2018/020968 WO2018165048A1 (en) 2017-03-06 2018-03-05 Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311312855.3A Division CN117398398A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Publications (1)

Publication Number Publication Date
CN110678186A true CN110678186A (zh) 2020-01-10

Family

ID=63448038

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880030083.5A Pending CN110678186A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
CN202311312855.3A Pending CN117398398A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311312855.3A Pending CN117398398A (zh) 2017-03-06 2018-03-05 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途

Country Status (16)

Country Link
US (4) US11091505B2 (https=)
EP (1) EP3592362B1 (https=)
JP (2) JP7634934B2 (https=)
KR (1) KR102603489B1 (https=)
CN (2) CN110678186A (https=)
AU (1) AU2018230991B2 (https=)
CA (1) CA3055253A1 (https=)
ES (1) ES3015371T3 (https=)
HR (1) HRP20250459T1 (https=)
IL (2) IL268981B2 (https=)
MA (1) MA47743A (https=)
MY (1) MY196966A (https=)
PH (1) PH12019502037B1 (https=)
PL (1) PL3592362T3 (https=)
SG (1) SG11201908181XA (https=)
WO (1) WO2018165048A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013355110B2 (en) 2012-12-07 2017-11-09 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) * 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026407A (zh) * 2012-12-07 2015-11-04 维纳拓尔斯制药公司 β-内酰胺酶抑制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7875642B2 (en) 2004-01-26 2011-01-25 Merck Sharp & Dohme Corp. Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1
HRP20212002T1 (hr) 2004-03-30 2022-04-01 Millennium Pharmaceuticals, Inc. Sinteza estera i spojeva borove kiseline
CN1965838A (zh) * 2005-11-17 2007-05-23 李海超 含头孢匹胺和β－内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2009091856A2 (en) 2008-01-18 2009-07-23 Merck & Co., Inc. Beta-lactamase inhibitors
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CA2807546C (en) 2010-08-10 2022-08-23 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013014497A1 (en) 2011-07-26 2013-01-31 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013053372A1 (en) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Boronic acid inhibitors of beta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
MX2015008627A (es) 2013-01-04 2015-09-23 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
EP2943204B1 (en) 2013-01-10 2019-03-13 Venatorx Pharmaceuticals Inc Beta-lactamase inhibitors
EP2970340B1 (en) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US9120796B2 (en) * 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (en) 2014-04-11 2015-10-15 The Texas A&M University System Novel inhibitors of the new delhi metallo beta lactamase (ndm-1)
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
WO2015191907A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
JP6218204B2 (ja) 2014-09-04 2017-10-25 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
MX389349B (es) 2016-06-30 2025-03-20 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos.
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
KR102603489B1 (ko) 2017-03-06 2023-11-16 에버레스트 메디신즈 (싱가포르) 피티이. 리미티드 베타-락타마제 억제제를 포함하는 고체 형태 및 조합 조성물과 이의 용도
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3849562B1 (en) 2018-09-12 2024-06-26 Venatorx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
BR112021010095A2 (pt) 2018-11-29 2021-09-28 VenatoRx Pharmaceuticals, Inc. Composições de combinação que compreendem um inibidor de beta-lactamase e usos das mesmas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105026407A (zh) * 2012-12-07 2015-11-04 维纳拓尔斯制药公司 β-内酰胺酶抑制剂

Also Published As

Publication number Publication date
US11091505B2 (en) 2021-08-17
KR102603489B1 (ko) 2023-11-16
IL301591B2 (en) 2026-03-01
IL301591B1 (en) 2025-11-01
US12187752B2 (en) 2025-01-07
MY196966A (en) 2023-05-15
IL268981B2 (en) 2023-09-01
HRP20250459T1 (hr) 2025-06-06
IL268981B1 (en) 2023-05-01
JP2023061946A (ja) 2023-05-02
AU2018230991A1 (en) 2019-09-19
BR112019018447A2 (pt) 2020-04-14
EP3592362A4 (en) 2020-09-02
PH12019502037A1 (en) 2020-03-09
KR20190117790A (ko) 2019-10-16
ES3015371T3 (en) 2025-05-05
EP3592362A1 (en) 2020-01-15
PH12019502037B1 (en) 2024-06-05
US20200010485A1 (en) 2020-01-09
SG11201908181XA (en) 2019-10-30
MA47743A (fr) 2020-01-15
AU2018230991B2 (en) 2023-07-13
WO2018165048A1 (en) 2018-09-13
EP3592362C0 (en) 2025-02-19
CA3055253A1 (en) 2018-09-13
JP2020510661A (ja) 2020-04-09
IL268981A (en) 2019-10-31
US20240101580A1 (en) 2024-03-28
PL3592362T3 (pl) 2025-06-23
EP3592362B1 (en) 2025-02-19
JP7634934B2 (ja) 2025-02-25
IL301591A (en) 2023-05-01
US20250320235A1 (en) 2025-10-16
US20220002322A1 (en) 2022-01-06
CN117398398A (zh) 2024-01-16
US11820784B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
US12187752B2 (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US10189833B2 (en) Solid forms of a compound modulating kinases
US10590089B2 (en) Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
TW202235417A (zh) 整合素抑制劑及其用途
HK40097446A (zh) 包含β-内酰胺酶抑制剂的固体形式和组合式组合物及其用途
US12030886B2 (en) Form of ponatinib
EA048377B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
HK40013654A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EA042812B1 (ru) Твердые формы и комбинированные композиции, содержащие ингибитор бета-лактамазы, и их применения
CN102770416B (zh) 美他沙酮共晶体
HK40020554B (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
HK40020554A (en) Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
BR112019018447B1 (pt) Forma cristalina anidra, mono-hidratada, composições farmacêuticas e usos das mesmas
NZ759132A (en) Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof
HK1248223B (en) Solid forms of a compound modulating kinases
HK1248223A1 (en) Solid forms of a compound modulating kinases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013654

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20230414

Address after: Singapore, Singapore City

Applicant after: Yunding Xinyao Singapore Ltd.

Address before: Pennsylvania, America

Applicant before: VENATORX PHARMACEUTICALS, Inc.

TA01 Transfer of patent application right